2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 13, 2019

11:00AM-12:30PM: Abstract Number: 2895

Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: Abstract Number: 2903

Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2927

Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative

6W026: Epidemiology & Public Health (2924–2929)

11:00AM-12:30PM: Abstract Number: 2906

DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2924

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?

6W026: Epidemiology & Public Health (2924–2929)

11:00AM-12:30PM: Abstract Number: 2909

Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2919

Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: Abstract Number: 2898

Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: Abstract Number: 2917

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2921

High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: Abstract Number: 2922

Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: Abstract Number: 2910

Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2897

Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: Abstract Number: 2900

Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2926

Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach

6W026: Epidemiology & Public Health (2924–2929)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].